ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/LIV1
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/LIV1
1
trial(s) found.
NCT03424005
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Treatment Combinations In Patients With Metastatic Breast Cancer (
Morpheus-panBC
)
AKT inhibitor
Abemaciclib
Atezolizumab
Bevacizumab
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
Capecitabine
Carboplatin
Eribulin
Fulvestrant
Gemcitabine
Inavolisib
Ipatasertib
Ladiratuzumab Vedotin
Letrozole
Nab-paclitaxel
PI3K alpha inhibitor
Ribociclib
Sacituzumab Govitecan
Selicrelumab
Tocilizumab
Trastuzumab Deruxtecan
agnostic antibody,CD40-targeting
anti-CD40 agonistic antibody
anti-ERBB2 antibody-drug conjugate
anti-IL-6 monoclonal antibody
anti-LIV1 antibody-drug conjugate
anti-PD-L1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
anti-VEGF monoclonal antibody
antimetabolite
aromatase inhibitor
cancer therapy
cancer therapy,AKT-targeting
cancer therapy,CD40-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,ERBB2-targeting
cancer therapy,ESR1-targeting
cancer therapy,IL-6-targeting
cancer therapy,LIV1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,Trop2-targeting
cancer therapy,VEGF-targeting
cytotoxic chemotherapy
endocrine therapy
endocrine therapy,oestrogen axis-targeting
fluoropyrimidine
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,CD40-targeting
immuno-oncology therapy,ERBB2-targeting
immuno-oncology therapy,IL-6-targeting
immuno-oncology therapy,LIV1-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,Trop2-targeting
immuno-oncology therapy,VEGF-targeting
macrocyclic ketone analogue
oestrogen receptor-targeting therapy
pan-AKT inhibitor
platinum-based antineoplastic agent
selective estrogen receptor degrader
taxane
+ anti-LIV1 antibody-drug conjugate
Breast cancer
VIC
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
WA
6150 - Murdoch - Fiona Stanley Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (1)
Recruitment Country and State
VIC (1)
WA (1)
Phase
Phase 1 / Phase 2 (1)
Trial Type
Advanced (1)
Cancer Therapy Class
AKT
100%
CD40
100%
CDK4
100%
CDK6
100%
ERBB2
100%
ER
100%
IL-6
100%
LIV1
100%
PD-1/PD-L1
100%
PD-L1
100%
PI3Kalpha
100%
Trop2
100%
VEGF
100%
oestrogen axis
100%
Facility
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus (1)
6150 - Murdoch - Fiona Stanley Hospital (1)
Cancer Type
Breast cancer
Cancer
Solid tumour
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy